Recent Updates
Recently added Catalysts
WAT

Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports Second Quarter 2020 Financial Results Sales of $520 million declined 13% as re

Key Takeaway: Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Corporation (NYSE: WAT) Reports Second Quarter 2020 Financial Results Milford, Mass., July 28, 2020 Waters Corporation (NYSE: WAT) today announced second quarter 2020 sales of $520 million, a 13%

Full Press Release Details

Contact: Bryan Brokmeier, CFA, Senior
Director, Investor Relations, 508-482-3448
Corporation (NYSE: WAT) Reports Second Quarter 2020 Financial Results
Milford, Mass., July 28, 2020 Waters Corporation (NYSE: WAT) today announced second quarter 2020 sales of $520 million, a 13% decrease
as reported, compared to sales of $599 million for the second quarter of 2019. Foreign currency translation negatively impacted sales growth by approximately 1% for the quarter. The Company s results were impacted by lower demand across
all major geographies due to the COVID-19 pandemic.
On a GAAP basis, diluted earnings per share (EPS) for the
second quarter of 2020 decreased to $1.98, compared to $2.08 for the second quarter of 2019. On a non-GAAP basis, EPS decreased to $2.10, compared to $2.14 in the second quarter of 2019. A description and reconciliation of GAAP to non-GAAP results
appear in the tables below and can be found on the Company s website at http://www.waters.com under the caption Investors.
basis, net cash provided by operating activities was $199 million for the second quarter of 2020, compared to $127 million for the second quarter of 2019. On a non-GAAP basis, adjusted free cash flow for the second quarter of
2020 was $175 million versus $136 million for the second quarter of 2019.
For the first half of 2020, the Company s sales
were $985 million, a decrease of 12% as reported, compared to sales of $1,113 million for the first half of 2019. Foreign currency translation negatively impacted sales growth by approximately 1% for the first half of 2020.
On a GAAP basis, EPS for the first half of 2020 decreased to $2.83, compared to $3.57 for the first half of 2019. On a non-GAAP basis, EPS decreased to $3.25,
compared to $3.73 in the first half of 2019.
On a GAAP basis, net cash provided by operating activities was $350 million for the first half of 2020,
compared to $303 million for the first half of 2019. On a non-GAAP basis, adjusted free cash flow for the first half of 2020 was $296 million versus $294 million for the first half of 2019.
As anticipated, our second quarter revenue declined due to the ongoing impacts of the COVID-19 pandemic. However, our results reflected modestly
better-than-anticipated market conditions and strong execution by our global sales, service and operations teams, commented Chris O Connell, President and Chief Executive Officer of Waters Corporation. This revenue performance,
combined with the benefits of our cost containment initiatives, drove solid margin and earnings results during the quarter. While risks and uncertainties remain in our operating environment, we are well-positioned to leverage our strong new product
pipeline and are investing to take advantage of growth opportunities as demand normalizes.
Unless otherwise noted, sales growth and decline percentages are presented on an as-reported basis and are the same as the sales growth and decline percentages presented on a constant-currency basis as compared with the same period in the prior year, each of which is detailed in the
reconciliation of sales growth rates to constant-currency growth rates in the tables below.
During the second quarter of 2020, sales into the
pharmaceutical market declined 11% as reported and 10% in constant currency, sales into the industrial market declined 14% as reported and 13% in constant currency and sales into the academic and governmental markets declined 22% as reported and 21%
in constant currency. For the first half of 2020, sales into the pharmaceutical market declined 9% as reported and 8% in constant currency, sales into the industrial market declined 11% as reported and 10% in constant currency and sales into the
academic and governmental markets declined 23% as reported and 22% in constant currency.
During the second quarter, recurring revenues, which represent
the combination of service and precision chemistries revenues, declined 4% as reported and 3% in constant currency, while instrument system sales declined 23% as reported and in constant currency. For the first half of 2020, recurring revenues
declined 3% as reported and 2% in constant currency, while instrument system sales declined 22% as reported and 21% in constant currency.
sales in Asia during the quarter declined 13% as reported and 12% in constant currency, sales in the Americas declined 15% (with U.S. sales declining 14%) and sales in Europe declined 11% as reported and 9% in constant currency. For the first half
of 2020, sales in Asia declined 16% as reported and 15% in constant currency, sales in the Americas declined 11% (with U.S. sales declining 9%) and sales in Europe declined 5% as reported and 3% in constant currency.
Waters Corporation will webcast its
second quarter 2020 financial results conference call today, July 28, 2020 at 8:00 a.m. Eastern Time. To listen to the call, please visit www.waters.com, choose Investors and click on the Live Webcast. A replay
will be available through August 4, 2020 at midnight Eastern Time on the same website by webcast and also by phone at 800-395-6236.
About Waters Corporation
Waters Corporation (NYSE: WAT),
the world s leading specialty measurement company, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years. With more than 7,000 employees worldwide,
Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries. For more information, visit www.waters.com.
Non-GAAP Financial Measures
This press release contains financial measures, such as constant-currency growth rate, adjusted operating income, adjusted net income, adjusted earnings per
diluted share and free cash flow, among others, which are considered non-GAAP financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company s
definitions of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this press release adjust for
specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management s financial and operational decision-making,
including evaluation of Waters Corporation s historical operating results, comparison to competitors operating results and determination of management incentive compensation. These non-GAAP
financial measures reflect an additional way of viewing aspects of the Company s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of
factors and trends affecting Waters Corporation s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company s reported results of
operations, management strongly encourages investors to review the Company s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial
measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.
Cautionary Statement
This release contains forward-looking statements regarding future results and events. For this purpose, any statements that are not statements of
historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words feels , believes , anticipates , plans , expects , intends , suggests ,
appears , estimates , projects and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. The Company s actual future results may differ significantly
from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, risks related to the effects of the COVID-19 pandemic on our
business, financial condition, results of operations and prospects, including: portions of our global workforce being unable to work fully and/or effectively due to working remotely, illness, quarantines, government actions, facility closures or
other reasons related to the pandemic, increased risks of cyber attacks resulting from our temporary remote working model, disruptions in our manufacturing capabilities or to our supply chain, volatility and uncertainty in global capital markets
limiting our ability to access capital, customers being unable to make timely payments for purchases and volatility in demand for our products; foreign exchange rate fluctuations potentially affecting translation of the Company s future non-U.S. operating results; the impact on demand for the Company s products among the Company s various market sectors or geographies from economic, sovereign and political uncertainties, particularly
regarding the effect of new or proposed tariff or trade regulations or changes in the interpretation or enforcement of existing regulations; the effect on the Company s financial results from the United Kingdom exiting the European Union;
fluctuations in expenditures by the Company s customers, in particular large pharmaceutical
companies; introduction of competing products by other companies and loss of market share; pressures on prices from competitors and/or customers; regulatory, economic and competitive obstacles to
new product introductions; other changes in demand for the Company s products from the effect of mergers and acquisitions by the Company s customers; increased regulatory burdens as the Company s business evolves, especially with
respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, among others; shifts in taxable income in jurisdictions with different effective tax rates; the outcome of tax examinations or changes in respective country
legislation affecting the Company s effective tax rate; the effect of the adoption of new accounting standards; the ability to access capital, maintain liquidity and service the Company s debt in volatile market conditions, particularly in
the U.S., as a large portion of the Company s cash is held and operating cash flows are generated outside the U.S.; environmental and logistical obstacles affecting the distribution of products and risks associated with lawsuits and other legal
actions, particularly involving claims for infringement of patents and other intellectual property rights. Such factors and others are discussed more fully in the sections entitled Forward-Looking Statements and Risk Factors
of the Company s annual report on Form 10-K for the year ended December 31, 2019, as well as in the sections entitled Special Note Regarding Forward-Looking Statements and
Risk Factors of the Company s quarterly report on Form 10-Q for the quarterly period ended June 27, 2020, each as filed with the Securities and Exchange Commission ( SEC ), which discussions are incorporated by
reference in this release, as updated by the Company s future filings with the SEC. The forward-looking statements included in this release represent the Company s estimates or views as of the date of this release and should not be relied
upon as representing the Company s estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.
Waters Corporation and Subsidiaries
Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
Three Months Ended Six Months Ended
June 27, 2020 June 29, 2019 June 27, 2020 June 29, 2019
Net sales $ 519,984 $ 599,162 $ 984,923 $ 1,113,024
Costs and operating expenses:
Cost of sales 213,134 249,546 423,778 470,577
Selling and administrative expenses 117,449 133,208 265,184 267,547
Research and development expenses 31,155 36,490 66,144 71,550
Purchased intangibles amortization 2,618 2,264 5,243 4,545
Litigation provision 514 1,180
Operating income 155,114 177,654 223,394 298,805
Other expense (736 ) (342 ) (1,110 ) (867 )
Interest expense, net (9,015 ) (5,577 ) (19,058 ) (8,825 )
Income from operations before income taxes 145,363 171,735 203,226 289,113
Provision for income taxes (1) 22,434 27,325 26,735 35,717
Net income $ 122,929 $ 144,410 $ 176,491 $ 253,396
Net income per basic common share $ 1.98 $ 2.09 $ 2.84 $ 3.60
Weighted-average number of basic common shares 61,944 68,989 62,085 70,331
Net income per diluted common share $ 1.98 $ 2.08 $ 2.83 $ 3.57
Weighted-average number of diluted common shares and equivalents 62,184 69,494 62,404 70,904
Waters Corporation and Subsidiaries
Reconciliation of GAAP to Adjusted Non-GAAP
Net Sales by Operating Segment, Products & Services, Geography and Markets
Three Months Ended June 27, 2020 and June 29, 2019
(In thousands)
Three Months Ended Percent Change Current Period Currency Impact Constant Currency Growth Rate (a)
June 27, 2020 June 29, 2019
NET SALES - OPERATING SEGMENT
Waters $ 465,709 $ 531,117 (12 %) $ (4,216 ) (12 %)
TA 54,275 68,045 (20 %) (292 ) (20 %)
Total $ 519,984 $ 599,162 (13 %) $ (4,508 ) (12 %)
NET SALES - PRODUCTS & SERVICES
Instruments $ 219,815 $ 286,973 (23 %) $ (728 ) (23 %)
Service 205,064 211,897 (3 %) (3,099 ) (2 %)
Chemistry 95,105 100,292 (5 %) (681 ) (4 %)
Total Recurring 300,169 312,189 (4 %) (3,780 ) (3 %)
Total $ 519,984 $ 599,162 (13 %) $ (4,508 ) (12 %)
NET SALES - GEOGRAPHY
Asia $ 208,209 $ 238,835 (13 %) $ (1,570 ) (12 %)
Americas 174,782 206,775 (15 %) (94 ) (15 %)
Europe 136,993 153,552 (11 %) (2,844 ) (9 %)
Total $ 519,984 $ 599,162 (13 %) $ (4,508 ) (12 %)
NET SALES - MARKETS
Pharmaceutical $ 311,018 $ 350,145 (11 %) $ (3,684 ) (10 %)
Industrial 152,110 176,109 (14 %) (314 ) (13 %)
Academic & Governmental 56,856 72,908 (22 %) (510 ) (21 %)
Total $ 519,984 $ 599,162 (13 %) $ (4,508 ) (12 %)
NET SALES - EXCLUDING CHINA
Total Net Sales $ 519,984 $ 599,162 (13 %) $ (4,508 ) (12 %)
China Net Sales 89,816 112,796 (20 %) (963 ) (20 %)
Total Net Sales Excluding China $ 430,168 $ 486,366 (12 %) $ (3,545 ) (11 %)
Waters Corporation and Subsidiaries
Reconciliation of GAAP to Adjusted Non-GAAP
Net Sales by Operating Segment, Products & Services, Geography and Markets
Six Months Ended June 27, 2020 and June 29, 2019
(In thousands)
Six Months Ended Percent Change Current Period Currency Impact Constant Currency Growth Rate (a)
June 27, 2020 June 29, 2019
NET SALES - OPERATING SEGMENT
Waters $ 879,920 $ 991,031 (11 %) $ (9,760 ) (10 %)
TA 105,003 121,993 (14 %) (1,145 ) (13 %)
Total $ 984,923 $ 1,113,024 (12 %) $ (10,905 ) (11 %)
NET SALES - PRODUCTS & SERVICES
Instruments $ 396,753 $ 508,223 (22 %) $ (3,879 ) (21 %)
Service 395,820 405,256 (2 %) (5,146 ) (1 %)
Chemistry 192,350 199,545 (4 %) (1,880 ) (3 %)
Total Recurring 588,170 604,801 (3 %) (7,026 ) (2 %)
Total $ 984,923 $ 1,113,024 (12 %) $ (10,905 ) (11 %)
NET SALES - GEOGRAPHY
Asia $ 367,289 $ 439,347 (16 %) $ (4,547) (15 %)
Americas 346,958 388,643 (11 %) 71 (11 %)
Europe 270,676 285,034 (5 %) (6,429 ) (3 %)
Total $ 984,923 $ 1,113,024 (12 %) $ (10,905) (11 %)
NET SALES - MARKETS
Pharmaceutical $ 583,581 $ 644,657 (9 %) $ (7,474 ) (8 %)
Industrial 295,464 331,327 (11 %) (1,935 ) (10 %)
Academic & Governmental 105,878 137,040 (23 %) (1,496 ) (22 %)
Total $ 984,923 $ 1,113,024 (12 %) $ (10,905 ) (11 %)
NET SALES - EXCLUDING CHINA
Total Net Sales $ 984,923 $ 1,113,024 (12 %) $ (10,905 ) (11 %)
China Net Sales 137,047 202,887 (32 %) (2,848 ) (31 %)
Total Net Sales Excluding China $ 847,876 $ 910,137 (7 %) $ (8,057 ) (6 %)
Waters Corporation and Subsidiaries
Reconciliation of GAAP to Adjusted Non-GAAP Financials
Three & Six Months Ended June 27, 2020 and June 29, 2019
(In thousands, except per share data)
Selling & Administrative Expenses (a) Operating Income Operating Income Percentage Other Expense Income from Operations before Income Taxes Provision for Income Taxes Net Income Diluted Earnings per Share
Quarter Ended June 27, 2020
GAAP $ 120,581 $ 155,114 29.8 % $ (736 ) $ 145,363 $ 22,434 $ 122,929 $ 1.98
Adjustments:
Purchased intangibles amortization (b) (2,618 ) 2,618 0.5 % 2,618 515 2,103 0.03
Restructuring costs and certain other items (c) (5,763 ) 5,763 1.1 % (152 ) 5,611 1,084 4,527 0.07
Litigation provisions (d) (514 ) 514 0.1 % 514 123 391 0.01
Certain income tax items (e) (507 ) 507 0.01
Adjusted Non-GAAP $ 111,686 $ 164,009 31.5 % $ (888 ) $ 154,106 $ 23,649 $ 130,457 $ 2.10
Quarter Ended June 29, 2019
GAAP $ 135,472 $ 177,654 29.7 % $ (342 ) $ 171,735 $ 27,325 $ 144,410 $ 2.08
Adjustments:
Purchased intangibles amortization (b) (2,264 ) 2,264 0.4 % 2,264 491 1,773 0.03
Restructuring costs and certain other items (c) (2,725 ) 2,725 0.5 % 2,725 640 2,085 0.03
Certain income tax items (e) (634 ) 634 0.01
Adjusted Non-GAAP $ 130,483 $ 182,643 30.5 % $ (342 ) $ 176,724 $ 27,822 $ 148,902 $ 2.14
Six Months Ended June 27, 2020
GAAP $ 271,607 $ 223,394 22.7 % $ (1,110) $ 203,226 $ 26,735 $ 176,491 $ 2.83
Adjustments:
Purchased intangibles amortization (b) (5,243 ) 5,243 0.5 % 5,243 1,037 4,206 0.07
Restructuring costs and certain other items (c) (26,283 ) 26,283 2.7 % (461 ) 25,822 5,681 20,141 0.32
Litigation provisions (d) (1,180 ) 1,180 0.1 % 1,180 283 897 0.01
Certain income tax items (e) (882 ) 882 0.01
Adjusted Non-GAAP $ 238,901 $ 256,100 26.0 % $ (1,571 ) $ 235,471 $ 32,854 $ 202,617 $ 3.25
Six Months Ended June 29, 2019
GAAP $ 272,092 $ 298,805 26.8 % $ (867 ) $ 289,113 $ 35,717 $ 253,396 $ 3.57
Adjustments:
Purchased intangibles amortization (b) (4,545 ) 4,545 0.4 % 4,545 985 3,560 0.05
Restructuring costs and certain other items (c) (12,786 ) 12,786 1.1 % 12,786 3,273 9,513 0.13
Tax reform (f) 3,229 (3,229 ) (0.05 )
Certain income tax items (e) (1,308 ) 1,308 0.02
Adjusted Non-GAAP $ 254,761 $ 316,136 28.4 % $ (867 ) $ 306,444 $ 41,896 $ 264,548 $ 3.73
Waters Corporation and Subsidiaries Preliminary Condensed Unclassified Consolidated Balance Sheets (In thousands and unaudited)
June 27, 2020 December 31, 2019
Cash, cash equivalents and investments $ 355,756 $ 337,144
Accounts receivable 496,276 587,734
Inventories 344,009 320,551
Property, plant and equipment, net 459,173 417,342
Intangible assets, net 248,993 240,203
Goodwill 427,492 356,128
Other assets 316,603 297,953
Total assets $ 2,648,302 $ 2,557,055
Notes payable and debt $ 1,696,159 $ 1,681,163
Other liabilities 1,143,885 1,092,173
Total liabilities 2,840,044 2,773,336
Total deficit (191,742 ) (216,281 )
Total liabilities and deficit $ 2,648,302 $ 2,557,055
Waters Corporation and Subsidiaries Preliminary Condensed Consolidated Statements of Cash Flows Three and Six Months Ended June 27, 2020 and June 29, 2019 (In thousands and unaudited)
Three Months Ended Six Months Ended
June 27, 2020 June 29, 2019 June 27, 2020 June 29, 2019
Cash flows from operating activities:
Net income $ 122,929 $ 144,410 $ 176,491 $ 253,396
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation 8,926 9,314 18,122 19,255
Depreciation and amortization 31,015 28,851 60,203 53,615
Change in operating assets and liabilities, net 35,941 (55,551 ) 95,630 (23,463 )
Net cash provided by operating activities 198,811 127,024 350,446 302,803
Cash flows from investing activities:
Additions to property, plant, equipment and software capitalization (45,899 ) (39,522 ) (97,029 ) (65,188 )
Business acquisitions, net of cash acquired (76,664 )
Investment in unaffiliated companies (3,350 ) (4,750 ) (3,350 ) (4,750 )
Net change in investments (12,911 ) 395,296 (15,292 ) 855,001
Net cash (used in) provided by investing activities (62,160 ) 351,024 (192,335 ) 785,063
Cash flows from financing activities:
Net change in debt (200,000 ) 32 14,634 118
Proceeds from stock plans 2,996 2,498 14,739 30,129
Purchases of treasury shares (71 ) (576,530 ) (196,297 ) (1,329,635 )
Other cash flow from financing activities, net 4,791 2,400 7,558 4,654
Net cash used in financing activities (192,284 ) (571,600 ) (159,366 ) (1,294,734 )
Effect of exchange rate changes on cash and cash equivalents 4,608 (3,420 ) 4,576 (1,414 )
(Decrease) increase in cash and cash equivalents (51,025 ) (96,972 ) 3,321 (208,282 )
Cash and cash equivalents at beginning of period 390,061 684,970 335,715 796,280
Cash and cash equivalents at end of period $ 339,036 $ 587,998 $ 339,036 $ 587,998
Reconciliation of GAAP Cash Flows from Operating Activities to Free Cash Flow (a)
Net cash provided by operating activities-GAAP $ 198,811 $ 127,024 $ 350,446 $ 302,803
Adjustments:
Additions to property, plant, equipment and software capitalization (45,899 ) (39,522 ) (97,029 ) (65,188 )
Tax reform payments 29,109 29,109
Major facility renovations 22,524 19,779 43,067 27,275
Free Cash Flow - Adjusted Non-GAAP $ 175,436 $ 136,390 $ 296,484 $ 293,999
Last updated: Jul 28, 2020